Scholar Rock

Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level.

They believe this approach, acting in the disease microenvironment, avoids the historical challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. The company is advancing its lead product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy, or SMA. They expect to initiate a Phase 1 clinical trial in the second quarter of 2018. Utilizing its proprietary platform, they are also creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia.

Scholar Rock headquartered in United States, North America, operates in the Biotechnology, Medical, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $42.5B in funding across 96 round(s). With a team of 101-250 employees, Scholar Rock is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Scholar Rock, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.